Business

BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial

Patients treated with BIV201 experienced reduced ascites fluid buildup

articleBiovie Inc.March 13, 20234/company/biovie-inc/news/biovie-announces-the-pausing-of-patient-enrollment-in-ascites-phase-2b-trial-encouraging-efficacy-data-is-announced-initiating-fda-discussions-to-conduct-pivotal-registrational-trial
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial

About this update from Biovie Inc.

[{"type":"text","content":"Patients treated with BIV201 experienced reduced ascites fluid buildup (p","length":77,"tagName":"div"}]

More updates from Biovie Inc.